UNSPSC 51281809: Mitoxantrone

This classification denotes an anthraquinone compound with the molecular formula C22H28N4O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BZ114NVM5P, chemically known as 9,10-anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)- (9ci) but generally known as mitoxantrone, which bears US NIH Compound Identifier 4212. European Medicines Agency schedules Mitoxantrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09012MIG.

UNSPSC 51281809 Mitoxantrone is a Commodity code that covers the supply of specific pharmaceutical products to state and local government health agencies. The recent opportunities tagged under this code show little actual mitoxantrone procurement; instead, the posted solicitations describe purchases of naloxone (an opioid-overdose reversal agent), doxycycline and ciprofloxacin (antibiotics), and drug deactivation systems. State and local buyers using this code appear to be public health departments and county health services seeking to stock emergency medications and harm-reduction supplies for community health initiatives and emergency preparedness. The issuing bodies include state health departments and county-level public health and community services agencies.

Geographic activity in the recent record centers on Florida and Illinois. Seminole County, Florida issued an IFB in June 2026 for naloxone and drug deactivation systems with a response deadline of July 26, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the Seminole County Community Health Building in Sanford, with an initial two-year term and one-year renewal option. Illinois Department of Public Health awarded a piggyback pharmaceutical supply contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026, for doxycycline hyclate and ciprofloxacin tablets totaling $2,999,999.11 over the contract life, with a 12-month initial term and renewal options for years 2 and 3. The mismatch between the code's nominal product (mitoxantrone, a chemotherapy agent) and the actual solicited goods (emergency and public-health medications) suggests this code may be misapplied to pharmaceutical inventory purchases or that recent opportunities have been miscategorized.